So now we can be pretty certain: the motive for submitting a petition for an inter partes review at the Patent Trial and Appeal Board is not important, what matters in the decision on whether it should be instituted is that it has a reasonable chance of success. That’s a big win for the likes of Kyle Bass and other hedge fund managers; and a concern for patent owners, not only in the life sciences industries, but also in many other sectors and, perhaps in particular, for public IP companies (PIPCOs).

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM is the only publication that places a business focus on intellectual property. Readers are given real insight into, and guidance on, managing intellectual property as a true business asset.

Marc Kaufman
Partner
Reed Smith LLP

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?